Skip to content
Search

Latest Stories

Girls have more grey matter, boys more white matter at birth: Study

brain-structures-at-birth-getty

Researchers from the University of Cambridge, UK, examined brain scans of over 500 newborns—236 girls and 278 boys—aged between 0 and 28 days. (Representational image: iStock)

A NEW study has found that newborn girls and boys have distinct brain structures at birth. While boys tend to have larger brains with more white matter, girls have significantly more grey matter, which is linked to learning, speech, and cognition.

Published in the journal Biology of Sex Differences, the study suggests these differences may result from biological sex-specific development in the womb.


White matter consists of long nerve fibres that connect neurons and facilitate communication between different parts of the brain.

Researchers from the University of Cambridge, UK, examined brain scans of over 500 newborns—236 girls and 278 boys—aged between 0 and 28 days.

"Our study settles an age-old question of whether male and female brains differ at birth. We know there are differences in the brains of older children and adults, but our findings show that they are already present in the earliest days of life," said lead researcher Yumnah Khan, a PhD student at the Autism Research Centre, University of Cambridge.

"Because these sex differences are evident so soon after birth, they might in part reflect biological sex differences during prenatal (pre-birth) brain development, which then interact with environmental experiences over time to shape further sex differences in the brain," Khan added.

After adjusting for total brain volume, the researchers examined specific brain regions. They found that, on average, girls had more grey matter in areas related to memory and emotion regulation, while boys had more grey matter in regions associated with processing sensations and motor control.

"On average, males had significantly larger intracranial and total brain volumes, even after controlling for birth weight," the study authors noted.

The researchers highlighted that these differences represent average trends and do not apply to all males or females.

"These differences do not imply the brains of males and females are better or worse. It's just one example of neurodiversity. This research may be helpful in understanding other kinds of neurodiversity, such as the brain in children who are later diagnosed as autistic, since this is diagnosed more often in males," said Simon Baron-Cohen, Director of the Autism Research Centre.

The study used data from the Developing Human Connectome Project, led by UK universities, including King’s College London, where newborns receive MRI brain scans shortly after birth.

(With inputs from PTI)

More For You

weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
Weight Loss Drug

Health officials expect the rollout to benefit around 220,000 adults over the next 3 years

iStock

NHS GPs to prescribe Mounjaro in nationwide obesity treatment plan

Key points

  • NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
  • The programme aims to support 220,000 people over three years
  • Eligible patients must have a BMI over 40 and at least four obesity-related health issues
  • GP leaders raise concerns over increased workload
  • Pharmacists urge a broader weight management approach

NHS expands obesity treatment with Mounjaro

The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.

Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.

Keep ReadingShow less
UK heatwave deaths

Around 85% of the projected deaths are likely to involve people over the age of 65

iStock

Scientists warn current UK heatwave may cause nearly 600 early deaths

Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.

Climate change driving deadly temperatures

Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.

Keep ReadingShow less
Amycretin

'The Lancet' and presentations at the American Diabetes Association’s 2025

iStock

New weight-loss pill Amycretin shows greater impact than jabs, study finds

A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.

Record weight loss from Amycretin injections

Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.

Keep ReadingShow less
Hulk Hogan

Hogan’s current hospital stay follows a neck fusion surgery he underwent in May 2025

Getty Images

Hulk Hogan hospitalised for back and neck issues, rep confirms he is not on deathbed

WWE Hall of Famer Hulk Hogan has been hospitalised for ongoing neck and back issues, but representatives have confirmed he is not in critical condition, dismissing online speculation suggesting otherwise.

The 71-year-old wrestling icon, whose real name is Terry Bollea, was reported by TMZ Sports to be undergoing treatment related to injuries sustained during his decades-long in-ring career. His representative said Hogan is already mobile again and “not on his deathbed”, following false claims made on air by Florida radio personality Bubba the Love Sponge.

Keep ReadingShow less